Pfizer clinical trial expert joins Bay Area Executive Breakfast roundtable

We've added our fifth and final panelist for the upcoming Executive Breakfast in San Francisco on April 13: Charles M. Baum, MD, PhD, the senior vice president for the biotechnology unit and oncology clinical research within Pfizer's Worldwide Research & Development division. Baum's an eight-year R&D veteran at Pfizer, where he's been responsible for the development of the company's oncology portfolio. His work includes the approval of Sutent for gastrointestinal stromal tumors.

Baum will join Deepak Srivastava, Director, Gladstone Institute of Cardiovascular Disease, Gisela Schwab, CMO at Exelixis, Mathai Mammen, the co-founder of Theravance and Susan Molineaux, CEO of Calithera, to give attendees some new ideas on the best way to shape and execute a clinical trial today.

This group brings together leading experts in the field from biotech, academia and Big Pharma who can offer some first-hand insights into the challenges confronted by today's clinical trial execs. And of course I'll be on hand to ask a few questions. Be sure to join us at the Hotel Nikko for one of the most unique clinical trial events of the year. Register here. -- John Carroll (email | twitter)

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.